TTrialPathMatch Me to Trials
← Back to trials
RecruitingLymphatic Malformation

Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Eligible age

0.5–18 yrs

Accepts

All genders

Locations

11 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity, and efficacy of intracystic injection of TARA-002 in participants 6 months to less than 18 years of age for the treatment of macrocystic and mixed cystic lymphatic malformations. The Phase 2a safety lead-in, age de-escalation study is designed to establish the safety of TARA-002 in older participants 6 years to less than 18 years before proceeding to younger participants 2 years to less than 6 years, then 6 months to less than 2 years. The Phase 2b is an expansion study in which enrollment of participants will be initiated after safety has been established in each cohort during the Phase 2a safety lead-in study. Each participant will receive up to 4 injections of TARA-002 spaced approximately 6 weeks apart.

Sponsor: Protara Therapeutics

You may qualify if…

  • ✓ Male or female participants 6 months to less than 18 years of age at the time of informed consent/assent form was signed
  • ✓ Participants whose parent/LAR(s) have voluntarily given written consent and participants who provided assent (if applicable) after the study has been explained to them
  • ✓ Participants with macrocystic LM or mixed cystic LM (≥ 50% macrocystic disease measured by volume) of the Head/Neck/Mediastinum according to the ISSVA 2018 criteria (ISSVA 2018) measured via LM imaging at Screening to confirm, upon central review, the diagnosis of macrocystic or mixed cystic LM
  • ✓ Participants who may have had surgical or sclerotherapy treatment for their LM, but not within six months of the consent/assent form being signed

You may not qualify if…

  • ✕ Penicillin allergy
  • ✕ Vascular tumors or combined vascular malformations
  • ✕ Microcystic LM or mixed cystic LM with predominant microcystic features
  • ✕ LMs of the orbit (orbital LM) as target cyst
  • ✕ For more information on eligibility criteria, please contact the sponsor.

Where it's recruiting

Alabama

Birmingham

Arkansas

Little Rock

Colorado

Aurora

District of Columbia

Washington D.C.

Florida

Jacksonville

New York

New York

Ohio

Cincinnati

Oregon

Portland

Pennsylvania

Philadelphia

Tennessee

Nashville

Virginia

Norfolk

Source: ClinicalTrials.gov · NCT05871970 · last updated 2026-08-24